You are here » Home » Companies » Company Overview » Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd.

BSE: 500009 Sector: Health care
NSE: AMBASARABH ISIN Code: INE432A01017
BSE LIVE 15:44 | 02 Dec 8.12 -0.16
(-1.93%)
OPEN

8.62

HIGH

8.62

LOW

7.95

NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 8.62
PREVIOUS CLOSE 8.28
VOLUME 29256
52-Week high 11.15
52-Week low 4.15
P/E
Mkt Cap.(Rs cr) 62.22
Buy Price 8.12
Buy Qty 70.00
Sell Price 0.00
Sell Qty 0.00
OPEN 8.62
CLOSE 8.28
VOLUME 29256
52-Week high 11.15
52-Week low 4.15
P/E
Mkt Cap.(Rs cr) 62.22
Buy Price 8.12
Buy Qty 70.00
Sell Price 0.00
Sell Qty 0.00

Ambalal Sarabhai Enterprises Ltd. (AMBASARABH) - Company History

Ambalal Sarabhai Enterprises Ltd produces a range of bulk drugs, pharmaceutical preparations and electronic instruments. The company operates in two segments, namely pharmaceuticals and electronics. Pharmaceuticals segment is engaged in manufacture of drugs and formulations. Electronics segment is engaged in manufacture of electronics instruments and services. Their subsidiaries include Synbiotics Ltd, Haryana Containers Ltd, Asence Inc, Asence Pharma Pvt Ltd, Mautik Exim Ltd, Systronics ( I ) Ltd, Suvik Hitek Pvt Ltd and Vovanties Lab Pvt Ltd. Ambalal Sarabhai Enterprises Ltd was incorporated on June 5, 1978. The company became a public limited company in December 1980. In the year 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 1997-98, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company. During the year 1998-99, the company signed agreement with B V Chiron, Netherlands for introducing their anti-cancer drugs in India. During the year 1999-2000, the company entered into an MoU for marketing of products of Oncology products of Chiron Corporation, USA. The product division essentially comprising of Sarabai Chemicals products was transferred to the joint venture company, Sarabhai Piramal Pharmaceuticals Ltd. In September 2008, the company acquired the manufacturing and marketing company, namely Suvik Hitek Pvt. Ltd. The Ethical Division re-launched the products of Suvik and Sarabhai Chemicals in market. Also, the company acquired Systronics (India) Pvt Ltd. During the year 2008-09, the Oncology Division launched two new products viz. Fludagem & Xtinib. Also, the company promoted a company viz. Vovanties Laboratories Pvt Ltd, a pharmaceutical specialist with a vision to establish a state of the art manufacturing facility specializing in Novel Effervescent drug delivery system. During the year 2010-11, the company has transferred and assigned as a going concern the undertaking and business of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and electronics division comprising of Systronics, Teleradand SERC to Systronics (India) Ltd with effect from October 01, 2010.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard